Cargando…

Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria

Stringent complete response (sCR) is defined as a deeper response than complete response (CR) in multiple myeloma. Whether achieving sCR correlates with better survival remains controversial. We evaluated the outcomes in patients with intact immunoglobulin multiple myeloma (IIMM) and light chain mul...

Descripción completa

Detalles Bibliográficos
Autores principales: Narita, Kentaro, Miura, Daisuke, Tsushima, Takafumi, Terao, Toshiki, Kuzume, Ayumi, Tabata, Rikako, Takeuchi, Masami, Matsue, Kosei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298479/
https://www.ncbi.nlm.nih.gov/pubmed/34294772
http://dx.doi.org/10.1038/s41598-021-94191-8
_version_ 1783726073069961216
author Narita, Kentaro
Miura, Daisuke
Tsushima, Takafumi
Terao, Toshiki
Kuzume, Ayumi
Tabata, Rikako
Takeuchi, Masami
Matsue, Kosei
author_facet Narita, Kentaro
Miura, Daisuke
Tsushima, Takafumi
Terao, Toshiki
Kuzume, Ayumi
Tabata, Rikako
Takeuchi, Masami
Matsue, Kosei
author_sort Narita, Kentaro
collection PubMed
description Stringent complete response (sCR) is defined as a deeper response than complete response (CR) in multiple myeloma. Whether achieving sCR correlates with better survival remains controversial. We evaluated the outcomes in patients with intact immunoglobulin multiple myeloma (IIMM) and light chain multiple myeloma (LCMM) who achieved a very good partial response (VGPR) or better. Multicolour flow cytometry was used to assess the depth of response. LCMM patients with sCR had significantly lower measurable residual disease (MRD) levels than those with CR (median MRD: 7.9 × 10(–4) vs. 5.6 × 10(–5), P < 0.01). Nonetheless, no significant difference was observed in MRD levels across the responses in groups of patients with IIMM (VGPR vs. CR: 3.5 × 10(–4) vs. 7.0 × 10(–5), P = 0.07; CR vs. sCR: 7.0 × 10(–5) vs. 5.4 × 10(–5), P = 0.81. In accordance with MRD levels, the median overall survival of patients with sCR was significantly longer (sCR, CR, VGPR; not reached, 41 months, and 58 months, respectively; VGPR vs. CR, P = 0.83; CR vs. sCR, P = 0.04) in LCMM, but not in IIMM (sCR, CR, VGPR; not reached, 41 months, and not reached, respectively; VGPR vs. CR, P = 0.59; CR vs. sCR; P = 0.10). Our results show that sCR represents a deeper response that correlates with longer survival in patients with LCMM, but not IIMM.
format Online
Article
Text
id pubmed-8298479
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82984792021-07-23 Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria Narita, Kentaro Miura, Daisuke Tsushima, Takafumi Terao, Toshiki Kuzume, Ayumi Tabata, Rikako Takeuchi, Masami Matsue, Kosei Sci Rep Article Stringent complete response (sCR) is defined as a deeper response than complete response (CR) in multiple myeloma. Whether achieving sCR correlates with better survival remains controversial. We evaluated the outcomes in patients with intact immunoglobulin multiple myeloma (IIMM) and light chain multiple myeloma (LCMM) who achieved a very good partial response (VGPR) or better. Multicolour flow cytometry was used to assess the depth of response. LCMM patients with sCR had significantly lower measurable residual disease (MRD) levels than those with CR (median MRD: 7.9 × 10(–4) vs. 5.6 × 10(–5), P < 0.01). Nonetheless, no significant difference was observed in MRD levels across the responses in groups of patients with IIMM (VGPR vs. CR: 3.5 × 10(–4) vs. 7.0 × 10(–5), P = 0.07; CR vs. sCR: 7.0 × 10(–5) vs. 5.4 × 10(–5), P = 0.81. In accordance with MRD levels, the median overall survival of patients with sCR was significantly longer (sCR, CR, VGPR; not reached, 41 months, and 58 months, respectively; VGPR vs. CR, P = 0.83; CR vs. sCR, P = 0.04) in LCMM, but not in IIMM (sCR, CR, VGPR; not reached, 41 months, and not reached, respectively; VGPR vs. CR, P = 0.59; CR vs. sCR; P = 0.10). Our results show that sCR represents a deeper response that correlates with longer survival in patients with LCMM, but not IIMM. Nature Publishing Group UK 2021-07-22 /pmc/articles/PMC8298479/ /pubmed/34294772 http://dx.doi.org/10.1038/s41598-021-94191-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Narita, Kentaro
Miura, Daisuke
Tsushima, Takafumi
Terao, Toshiki
Kuzume, Ayumi
Tabata, Rikako
Takeuchi, Masami
Matsue, Kosei
Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria
title Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria
title_full Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria
title_fullStr Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria
title_full_unstemmed Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria
title_short Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria
title_sort quantification of measurable residual disease in patients with multiple myeloma based on the imwg response criteria
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298479/
https://www.ncbi.nlm.nih.gov/pubmed/34294772
http://dx.doi.org/10.1038/s41598-021-94191-8
work_keys_str_mv AT naritakentaro quantificationofmeasurableresidualdiseaseinpatientswithmultiplemyelomabasedontheimwgresponsecriteria
AT miuradaisuke quantificationofmeasurableresidualdiseaseinpatientswithmultiplemyelomabasedontheimwgresponsecriteria
AT tsushimatakafumi quantificationofmeasurableresidualdiseaseinpatientswithmultiplemyelomabasedontheimwgresponsecriteria
AT teraotoshiki quantificationofmeasurableresidualdiseaseinpatientswithmultiplemyelomabasedontheimwgresponsecriteria
AT kuzumeayumi quantificationofmeasurableresidualdiseaseinpatientswithmultiplemyelomabasedontheimwgresponsecriteria
AT tabatarikako quantificationofmeasurableresidualdiseaseinpatientswithmultiplemyelomabasedontheimwgresponsecriteria
AT takeuchimasami quantificationofmeasurableresidualdiseaseinpatientswithmultiplemyelomabasedontheimwgresponsecriteria
AT matsuekosei quantificationofmeasurableresidualdiseaseinpatientswithmultiplemyelomabasedontheimwgresponsecriteria